Back to search results

Fast TILs for Metastatic Cancer with Pleural Disease

This study is testing a new immunotherapy called Fast TILs to treat cancers that have spread to the lining of the lungs (pleura) or malignant mesothelioma. This treatment uses your own immune cells, specifically T-cells from your pleural fluid, which are grown in a lab at AHN West Penn. These special cells are then put back into your chest through a catheter, along with a drug called Interleukin-2 (IL-2). The main goal is to see if this treatment can be made locally and if it's safe. You might be able to join if you are between 18 and 79 years old, have cancer that has spread to your pleura or mesothelioma with fluid buildup, and standard treatments haven't worked. The study plans to enroll 10 participants, but its current status is unclear.

Study design
This is a first-in-human, single-arm study (meaning all participants receive the same treatment) that plans to enroll 10 participants.
What's involved
You will have pleural fluid collected, undergo chemotherapy, and then receive the Fast TILs and Interleukin-2 through a pleural catheter.
Compensation
Not stated in the trial record.
Follow-up
The feasibility of manufacturing the treatment is measured at 30 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07192900

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

Recruiting
PHASE1Ages 18–79InterventionalTreatment
David Bartlett, MD
~10 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:locally manufactured adoptive cellular therapy (ACT) productInterleukin-2

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device
Measured over 30 days
+3 more outcomes measured

Conditions

Malignant Pleural Effusion
Malignant Mesothelioma
Pleural Effusion, Malignant
Metastasis to Pleura

Explore related trials

Malignant MesotheliomaMalignant Pleural Effusion

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • David Bartlett, MD · PRINCIPAL_INVESTIGATOR · Allegheny Health Network

Who to contact

David Bartlett, MD
[email protected]
412-359-3731
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device30 days

    flow cytometry for cellular ACT identity

  • Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device30 days

    cytotoxicity assays for ACT potency

  • Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device30 days

    flow cytometry for cellular ACT purity

  • To demonstrate the safety of intrapleural administration of the locally manufactured ACT product plus Interleukin 2 (IL-2) to study patients5 years

    incidence of Treatment-Emergent Adverse Events (Safety) of intrapleural administration of the locally manufactured ACT product, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.